Key Findings
ProBio’s exceptional AAV (adeno-associated virus) manufacturing technology is robustly supporting pre-Investigational New Drug (IND) research for the first-in-class pan-cancer CAR-T program developed collaboratively by the University of California, Irvine (UC Irvine) and GlyTR Therapeutics. The GMP-compliant AAV6 product provided by ProBio achieved a high CAR gene insertion efficiency of approximately 80% and demonstrated potent efficacy in efficiently eliminating tumors in mouse models. This achievement marks a significant step towards the development and rapid clinical translation of next-generation CAR-T cell therapies.
Technical / Clinical Details
UC Irvine and GlyTR Therapeutics are developing a novel CAR-T cell therapy targeting solid tumors, utilizing ProBio’s AAV manufacturing technology for gene delivery. ProBio offers integrated CDMO (Contract Development and Manufacturing Organization) capabilities, spanning from plasmid DNA development to GMP (Good Manufacturing Practice) manufacturing and scalable Chemistry, Manufacturing, and Controls (CMC) expertise. Specifically, ProBio supplied the AAV scale-up materials necessary for IND application, supporting the evaluation of safety and efficacy during preclinical stages.
The provided AAV6 viral vector boasts high titer and purity, enabling efficient delivery of the CAR gene into target cells. The approximately 80% CAR gene insertion efficiency means that a large proportion of cells express the therapeutic CAR, which is crucial for maximizing treatment success. The high tumor elimination efficacy in animal models suggests that this CAR-T cell therapy candidate possesses potent anti-tumor activity, providing strong justification for its transition to human clinical trials.
Background & Context
While CAR-T cell therapies have achieved groundbreaking success in hematological cancers, their efficacy against solid tumors remains a challenge. Therefore, developing ‘pan-cancer CAR-T’ therapies effective against solid tumors is one of the most critical priorities in the oncology field. AAV vectors are gaining attention as a safe and versatile tool for gene delivery into various cell types, making them an attractive non-viral or hybrid gene delivery approach for CAR-T cell manufacturing. Partnerships with experienced CDMOs like ProBio are essential for overcoming manufacturing bottlenecks and accelerating innovation in the complex development of cell and gene therapy products.
Strategic Significance & Outlook
The pan-cancer CAR-T program by UC Irvine and GlyTR Therapeutics, bolstered by ProBio’s AAV manufacturing technology, is poised to open new possibilities for solid tumor treatment. Success in IND application and subsequent favorable clinical trial results are highly anticipated. This collaboration serves as an excellent example of how CDMOs, by providing advanced manufacturing capabilities and expertise, enable academic institutions and emerging biotechnology companies to rapidly develop and deliver innovative cell and gene therapies to patients. ProBio is expected to further enhance the scalability and efficiency of its AAV manufacturing, supporting an increasing number of advanced cell and gene therapy pipelines in the future.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments